A Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers
13. juli 2026 oppdatert av: RAI Services Company
A Multi-Site Two-Arm Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Combustible Cigarette Smokers
The goal of this study is to evaluate the rate of end of study complete cigarette reduction in health adult consumers of cigarettes when given access to a heated tobacco product (HTP).
The primary study objective is to evaluate the impact of access to HTP Device 1 or HTP Device 2 and a single stick variant on the rate of final 7-day abstinence from smoking cigarettes among U.S. adult smokers at the end of a 3-month study period.
Studieoversikt
Status
Rekruttering
Intervensjon / Behandling
Detaljert beskrivelse
This will be a multi-site, open-label, two-arm study to evaluate the rate of end of study complete combustible cigarette (CC) reduction in healthy adult consumers of CC when given access to a heated tobacco product (HTP) device (glo or glo plus), with one of four variants of HTP consumables (also known as "sticks" or "stick variants", under the brand name "virto") over a 3-month (90-day) actual use period (AUP).
Studietype
Intervensjonell
Registrering (Antatt)
1060
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Emily Smith
- Telefonnummer: 336-741-2396
- E-post: smithe13@rjrt.com
Studiesteder
-
-
Florida
-
Brandon, Florida, Forente stater, 33511
- Rekruttering
- Opinions Brandon
-
Coral Springs, Florida, Forente stater, 33071
- Rekruttering
- Opinions Coral Springs
-
-
Illinois
-
Aurora, Illinois, Forente stater, 60504
- Rekruttering
- Opinions Chicago
-
Gurnee, Illinois, Forente stater, 60031
- Rekruttering
- Opinions Chicago
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89107
- Rekruttering
- Opinions Las Vegas
-
Las Vegas, Nevada, Forente stater, 89119
- Rekruttering
- Opinions Las Vegas
-
-
Texas
-
Fort Worth, Texas, Forente stater, 76132
- Rekruttering
- Opinions Fort Worth
-
Houston, Texas, Forente stater, 77070
- Rekruttering
- Opinions Houston
-
Hurst, Texas, Forente stater, 76053
- Rekruttering
- Opinions Dallas
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Able to read, understand, and are willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English.
- Generally healthy male or female, between 21 and 65 years of age, inclusive, at the time of consent, verified with government-issued identification.
- All female (assigned at birth) candidate participants who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant. Note: Participants who identify as "intersex" or "unknown" during screening, will be required to take a pregnancy test if they wish to take one.
- Currently smoke at least five combustible cigarettes on smoking days in the past 30 days.
- Smoke combustible cigarettes on 15 or more of the past 30 days.
- Smoked at least 100 factory-made filtered menthol and/or non-menthol combustible cigarettes in their lifetime prior to the Site Enrollment Visit.
- Must indicate a neutral/positive intention to use at least one stick variant at the Site Enrollment Visit.
- Own a smartphone (iOS or Android) with internet access to download a study application to access surveys and the capability to receive notifications.
- Agree to participate in the study and to abide by the study restrictions and requirements, as described in the ICF.
- Must try all four stick variants during the 1-week product trial period.
- Must indicate a neutral/positive intention to use at least one stick variant following the product trial period.
Exclusion Criteria:
- Female participants who are pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report.
- Male participants who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or refrain from donating sperm from the time of the signing of the ICF until the end of the study, unless they have undergone a vasectomy or are abstinent from heterosexual intercourse, or their female partner was not able to bear children.
- Female participants who self-report not using adequate methods to prevent pregnancy.
- Persons with pacemakers or other embedded electronic medical devices fitted.
- Participants who self-report having an unstable heart condition, severe hypertension, or diabetes.
- Individuals who respond with 'Poor' or 'Don't know' to general physical or mental health.
- Participants who have used electronic nicotine delivery system (ENDS), nicotine pouches, HTP or smokeless tobacco (i.e., chewing tobacco, snus, or snuff) products, other combustible tobacco/nicotine products, and other oral nicotine products (tablets, gums, and lozenges) on 5 or more days in the past 30 days.
- Participants who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.
- Employee of a company that manufactures tobacco or HTPs.
- Persons who are personally, have household members, or have close family or friends in litigation with a company that manufactures tobacco or HTPs.
- Have taken part in a tobacco/nicotine research study in the past 30 days.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: HTP Device 1
HTP Device (One Piece) with two menthol and two tobacco stick variants
|
Tobacco Flavor #1
Tobacco Flavor #2
Menthol #1
Menthol #2
|
|
Aktiv komparator: HTP Device 2
HTP Device (Two Piece) with two menthol and two tobacco stick variants
|
Tobacco Flavor #1
Tobacco Flavor #2
Menthol #1
Menthol #2
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number and proportion of participants self-reporting past 7-day complete combustible cigarette reduction (abstinence) during the final 7 days of the 3-month (90-day) study period in each study arm and by stick variant within the study arm.
Tidsramme: 7 days
|
7 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The number and proportion of participants who completely switch from combustible cigarette smoking to HTP device 1 or HTP device 2 during the entire final 7 days of the 3 month study period in each study arm and by stick variant within the study arm.
Tidsramme: 7 days
|
7 days
|
|
The number and proportion of participants who reduce their combustible cigarettes by more than or equal to 50% within their average weekly cigarettes per day from baseline to final 7 days of the study period in each study arm and by stick variant.
Tidsramme: 3 months
|
3 months
|
|
The time to first 7-day abstinence of combustible cigarettes by participants in each study arm and by stick variant within each study arm
Tidsramme: 3 months
|
3 months
|
|
The weekly mean percent cigarettes per day reductions from baseline in each study arm and by stick variant within each arm
Tidsramme: 3 months
|
3 months
|
|
The number and type of adverse experiences/events in relation to use of the Study IP in each study arm and by stick variant within each study arm
Tidsramme: 3 months
|
3 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. juli 2026
Primær fullføring (Antatt)
1. desember 2026
Studiet fullført (Antatt)
1. desember 2026
Datoer for studieregistrering
Først innsendt
13. juli 2026
Først innsendt som oppfylte QC-kriteriene
13. juli 2026
Først lagt ut (Faktiske)
17. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
17. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
13. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PHI252504
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .